Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Merck's stock is suddenly soaring, but is the struggling healthcare giant a buy? Merck shares began peeling back in early ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

On Friday, Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESAIY) (OTC:ESALF) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib), in combination ...